These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20503409)

  • 21. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.
    Zuo Y; Wu Y; Chakraborty C
    J Cell Physiol; 2012 Apr; 227(4):1399-407. PubMed ID: 21618528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of RhoA-GTP induces activation of the Epidermal Growth Factor Receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells.
    Cáceres M; Guerrero J; Martínez J
    Exp Cell Res; 2005 Sep; 309(1):229-38. PubMed ID: 15963982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates.
    Yamazaki D; Kurisu S; Takenawa T
    Oncogene; 2009 Apr; 28(13):1570-83. PubMed ID: 19234490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.
    Pan Q; Bao LW; Kleer CG; Sabel MS; Griffith KA; Teknos TN; Merajver SD
    Cancer Res; 2005 Sep; 65(18):8366-71. PubMed ID: 16166314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myosin-interacting guanine exchange factor (MyoGEF) regulates the invasion activity of MDA-MB-231 breast cancer cells through activation of RhoA and RhoC.
    Wu D; Asiedu M; Wei Q
    Oncogene; 2009 Jun; 28(22):2219-30. PubMed ID: 19421144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bombesin stimulates invasion and migration of Isreco1 colon carcinoma cells in a Rho-dependent manner.
    Saurin JC; Fallavier M; Sordat B; Gevrey JC; Chayvialle JA; Abello J
    Cancer Res; 2002 Aug; 62(16):4829-35. PubMed ID: 12183443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rho GTPases and regulation of hematopoietic stem cell localization.
    Williams DA; Zheng Y; Cancelas JA
    Methods Enzymol; 2008; 439():365-93. PubMed ID: 18374178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma.
    Bellovin DI; Simpson KJ; Danilov T; Maynard E; Rimm DL; Oettgen P; Mercurio AM
    Oncogene; 2006 Nov; 25(52):6959-67. PubMed ID: 16715134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells.
    Wu M; Wu ZF; Kumar-Sinha C; Chinnaiyan A; Merajver SD
    Breast Cancer Res Treat; 2004 Mar; 84(1):3-12. PubMed ID: 14999149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive regulation of migration and invasion by vasodilator-stimulated phosphoprotein via Rac1 pathway in human breast cancer cells.
    Han G; Fan B; Zhang Y; Zhou X; Wang Y; Dong H; Wei Y; Sun S; Hu M; Zhang J; Wei L
    Oncol Rep; 2008 Oct; 20(4):929-39. PubMed ID: 18813837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase.
    Shi HY; Stafford LJ; Liu Z; Liu M; Zhang M
    Cell Motil Cytoskeleton; 2007 May; 64(5):338-46. PubMed ID: 17301947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
    Kleer CG; Griffith KA; Sabel MS; Gallagher G; van Golen KL; Wu ZF; Merajver SD
    Breast Cancer Res Treat; 2005 Sep; 93(2):101-10. PubMed ID: 16187229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insight into the 6-thiopurine-mediated termination of the invasive motility of tumor cells derived from inflammatory breast cancer.
    Heo J; Wey M; Hong I
    Biochemistry; 2011 Jun; 50(25):5731-42. PubMed ID: 21568348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).
    Malissein E; Meunier E; Lajoie-Mazenc I; Médale-Giamarchi C; Dalenc F; Doisneau-Sixou SF
    J Cancer Res Clin Oncol; 2013 Dec; 139(12):2079-88. PubMed ID: 24096540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced intrinsic migration of aggressive breast cancer cells by inhibition of Rac1 GTPase.
    Zuo Y; Shields SK; Chakraborty C
    Biochem Biophys Res Commun; 2006 Dec; 351(2):361-7. PubMed ID: 17064663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
    Zhao Y; Zong ZH; Xu HM
    Gynecol Oncol; 2010 Mar; 116(3):563-71. PubMed ID: 20022093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
    Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
    J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rho isoform-specific interaction with IQGAP1 promotes breast cancer cell proliferation and migration.
    Casteel DE; Turner S; Schwappacher R; Rangaswami H; Su-Yuo J; Zhuang S; Boss GR; Pilz RB
    J Biol Chem; 2012 Nov; 287(45):38367-78. PubMed ID: 22992742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma.
    Horiuchi A; Imai T; Wang C; Ohira S; Feng Y; Nikaido T; Konishi I
    Lab Invest; 2003 Jun; 83(6):861-70. PubMed ID: 12808121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RhoA and RhoC have distinct roles in migration and invasion by acting through different targets.
    Vega FM; Fruhwirth G; Ng T; Ridley AJ
    J Cell Biol; 2011 May; 193(4):655-65. PubMed ID: 21576392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.